Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry

Abstract

In PsA, smokers had worse baseline patient-reported outcomes, shorter treatment adherence and poorer response to TNFi's compared to non-smokers. This was most pronounced in men and in patients treated with infliximab or etanercept.

Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population‐Based Cohort Study

“…The most common reasons for discontinuation of TNFi treatment in PsA are lack of efficacy and, to a lesser extent, adverse events . Moreover, previous studies have identified other factors that seem to influence TNFi outcomes in PsA, including baseline C‐reactive protein (CRP) level, concomitant methotrexate treatment, sex, and body mass index (BMI) . However, few previous studies have investigated whether the number and severity of somatic and psychiatric comorbid diseases influence TNFi treatment response and persistence in patients with PsA .…”

Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis

“…Smokers have also been shown to have a shorter treatment adherence and a poorer response to TNFi in psoriatic arthritis 5. The impact of tobacco use in patients with axial spondyloarthritis (axSpA) is only beginning to emerge.…”

Critical role of environmental factors in the pathogenesis of psoriasis

“…Studies have showed that smoking can increase the activity of spondyloarthritis and rheumatoid arthritis, thus reducing quality of life. [61][62][63] Hojgaard et al 64 conducted an observational research of 1388 psoriatic patients to study the correlation between smoking and treatment effect of TNF-a inhibitors. The result showed that heavy smoking could decrease the treatment effect of TNF-a-targeted drugs, and the impact seemed partially reversible.…”